Weight Loss in Adults Using Semaglutide (Real-world Study)

NCT07627074 | Recruiting

• 2 other identifiers: NN9536-8874U1111-1338-2016
• Study Type: observational
• Target: 35,000
• Locations: 2 countries
• Sites: 2

Brief Summary

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Conditions

Obesity; Overweight

Outcome Measures

Primary Outcomes (3)

• Change in body weight

  Measured as kilogram (kg)

  From index date (day 0) to week 68 (day 476)

• Change in body weight

  Measured as percentage (%)

  From index date (day 0) to week 68 (day 476)

• Proportion of individuals achieving a clinically meaningful weight loss

  Binary (yes/no): estimated ≥5% reduction from baseline body weight

  From index date (day 0) to week 68 (day 476)

Study Arms (1)

Semaglutide

Adults initiating semaglutide in routine clinical care and assigned to 0.5, 1.0, 1.7 or 2.4 mg at approximately Week 20. Participants are followed from treatment initiation up to 68 weeks using data collected during routine clinical practice. No study-specific interventions, visits, or procedures are performed. Data are derived from secondary use of routinely collected healthcare data.

Drug: Semaglutide

Interventions

Semaglutide DRUG

This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Semaglutide

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population comprises adults initiating semaglutide in routine clinical practice.

You may qualify if:

• Initiation of semaglutide for weight management during the study period.
• Age more than or equal to (≥) 18 at treatment initiation
• Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.

You may not qualify if:

• Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
• Bariatric surgery at baseline.
• Diabetes at baseline.
• Pregnancy at baseline.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (2)

Novo Nordisk Investigational Site

Seattle, Washington, 98039, United States

RECRUITING

Novo Nordisk Investigational Site

London, United Kingdom

RECRUITING

MeSH Terms

Conditions

Overweight; Obesity

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Central Study Contacts

Novo Nordisk

CONTACT

(+1) 866-867-7178; clinicaltrials@novonordisk.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 30, 2026
• First Posted: June 4, 2026
• Study Start: May 12, 2026
• Primary Completion: June 1, 2026
• Study Completion: June 1, 2026
• Last Updated: June 4, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share

Locations

GB (1); US (1)